Development of novel targeted therapy for lung cancer with activating Ras mutation
| Project/Area Number |
23790903
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
TAKEUCHI Shinji 金沢大学, がん進展制御研究所, 助教 (90565384)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 肺がん / Ras / ROS / 肺癌 / 活性酸素 |
|---|
| Research Abstract |
There are still no effective targeted therapies for patients with K-ras activating mutations which is a cause of intrinsic resistance to EGFR-TKI. Here, we assessed therapeutic effect of β-phenylthyl isothiocynate (PEITC) on lung cancer cellswith K-ras activating mutations through production of reactive oxygen species (ROS).Treatment with PEITC reduced cell viability and induced apoptosis in K-ras mutant lung cancer cells. In a xenograft model, PEITC dramatically reduced tumor growth with less toxicity. Moreover, normal human fibloblasts and K-ras wild lung cancer cells weresignificantly less sensitive to PEITC. Our findings suggest that PEITC can selectively kill lung cancer cells with K-ras activating mutations.
|
Report
(3 results)
Research Products
(19 results)
-
-
-
[Journal Article] Dual inhibition of met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer2012
Author(s)
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano
-
Journal Title
Am J Pathol
Volume: 181
Issue: 3
Pages: 1034-1043
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells2012
Author(s)
Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S
-
Journal Title
Clin Cancer Res
Volume: 18
Issue: 6
Pages: 1663-71
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort2011
Author(s)
Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
-
Journal Title
J Thorac Oncol
Volume: 6
Issue: 12
Pages: 2011-7
DOI
Related Report
Peer Reviewed
-
[Journal Article] E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor2011
Author(s)
Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
-
Journal Title
Mol Cancer Ther
Volume: 10
Issue: 7
Pages: 1218-28
DOI
Related Report
Peer Reviewed
-
-
-
-
-
[Presentation] Met/VEGFR-2阻害剤E7050は変異型EGFR肺がんにおいてHGFによるEGFR-TKI耐性誘導を克服する2011
Author(s)
竹内 伸司, Wang Wei, Li Qi, 山田 忠明, Donev Ivan, 小泉 瞳, 中村 隆弘, 松本 邦夫, 西岡 安彦, 曽根 三郎, 上仲 俊光, 矢野 聖二
Organizer
第70回日本がん学会学術総会
Year and Date
2011-10-03
Related Report
-
-
-
